Medication info
Lansoq Capsule 30 mg (Lansoprazole Granules)

Lansoq Capsule 30 mg (Lansoprazole Granules)

Prescription medicationHard capsuleOral
Ingredient · strength
Lansoprazole Granules›353mg / 1 capsule
Manufacturer / importer
White Life Science Co., Ltd.
Appearance
White to light brown granules contained in a white hard capsule for the upper and lower parts.
Packaging
28 capsules/bottle
Approval status
Active

MFDS item code 201603084 · Approved 2016.05.31 · Insurance code 625201360

Summary

Main use
Treatment and prevention of gastric and duodenal ulcers, Helicobacter pylori infection, gastroesophageal reflux, and gastric acid hypersecretion
Who takes it
Adults · Children
Adult dose
This medicine should be administered before meals. For patients who have difficulty swallowing the medication, open the capsule, mix this medicine with a small amount (60 mL) of orange juice or tomato juice, and administer immediately. Rinse the glass with 2 times or more juice to ensure the entire dose is taken, and drink immediately. After opening the capsule, do not chew or crush the contents before taking them. Short-term treatment of active duodenal ulcer: Administer lansoprazole 15 mg orally once daily for 4 weeks. Short-term treatment of active benign gastric ulcer: Administer lansoprazole 30 mg orally once daily for 8 weeks. Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence: Administer lansoprazole 30 mg with clarithromycin 250 ∼ 500 mg and amoxicillin 1,000 mg twice daily (every 12 hours) for 7 days. Treatment may be continued for up to 14 days if necessary. Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence: Administer lansoprazole 30 mg in combination with amoxicillin 1,000 mg three times daily (every 8 hours) for 14 days. Maintenance treatment after treatment of duodenal ulcer: Administer lansoprazole 15 mg orally once daily. The comparative clinical trial period did not exceed 12 months. Treatment of nonsteroidal anti-inflammatory drug-induced gastric ulcer: Administer lansoprazole 30 mg orally once daily for 8 weeks. The comparative clinical trial period did not exceed 8 weeks. Reduction of the risk of nonsteroidal anti-inflammatory drug-induced gastric ulcer: Administer lansoprazole 15 mg orally once daily for 12 weeks. The comparative clinical trial period did not exceed 12 weeks. Short-term treatment of symptoms associated with gastroesophageal reflux disease: Administer lansoprazole 15 mg orally once daily for 8 weeks. Short-term treatment of erosive reflux esophagitis: Administer lansoprazole 30 mg orally once daily for 8 weeks. Maintenance treatment after treatment of erosive reflux esophagitis: Administer lansoprazole 15 mg orally once daily. Pathological hypersecretory conditions, including Zollinger-Ellison syndrome: The lansoprazole dose for pathological hypersecretory conditions varies by patient. Treatment in adults is usually initiated at 60 mg once daily. The dose should be adjusted according to the patient's needs and may be continued for as long as it is clinically effective. Doses of 90 mg twice daily have been administered. If the daily dose exceeds 120 mg, it should be divided. Since clearance of this medicine is reduced in elderly patients, dose adjustment is necessary. Do not exceed a daily dose of 30 mg. Since metabolism and excretion of this medicine may be delayed in patients with hepatic impairment, administer with caution, including dose adjustment as appropriate.
Child dose
Pediatric patients and adolescents aged 12 ∼ 17 years — Short-term treatment of symptoms associated with nonerosive gastroesophageal reflux disease: 15 mg once daily for 8 weeks Pediatric patients and adolescents aged 12 ∼ 17 years — Short-term treatment of erosive reflux esophagitis: 30 mg once daily for 8 weeks Pediatric patients aged 1 ∼ 11 years, weighing 30 kg or less — Short-term treatment of symptoms associated with gastroesophageal reflux disease and erosive reflux esophagitis: 15 mg once daily for 12 weeks Pediatric patients aged 1 ∼ 11 years, weighing more than 30 kg — Short-term treatment of symptoms associated with gastroesophageal reflux disease and erosive reflux esophagitis: 30 mg once daily for 12 weeks

Ingredients

Manufacturer
White Life Science Co., Ltd.

Efficacy & effects

Treatment and prevention of gastric and duodenal ulcers, Helicobacter pylori infection, gastroesophageal reflux, and gastric acid hypersecretion

  • Active duodenal ulcers
  • active benign gastric ulcers
  • duodenal ulcers
  • NSAID-induced gastric ulcers
  • gastroesophageal reflux disease-related symptoms
  • erosive esophagitis
  • Zollinger-Ellison syndrome
  • pathological hypersecretion states.
View approved original text

This medication is used for the short-term treatment of active duodenal ulcers and benign gastric ulcers. It is also effective for the eradication of Helicobacter pylori to prevent the recurrence of duodenal ulcers. It can be used in maintenance therapy after treatment and helps in the treatment and reduction of the risk of gastric ulcers induced by non-steroidal anti-inflammatory drugs (NSAIDs). It is used for the short-term treatment of gastroesophageal reflux disease and erosive esophagitis, as well as for maintenance therapy after treatment, and it controls pathological gastric acid hypersecretion states such as Zollinger-Ellison syndrome. It is widely used for various gastrointestinal-related diseases, effectively improving symptoms.

How to take

Adult dose

This medicine should be administered before meals. For patients who have difficulty swallowing the medication, open the capsule, mix this medicine with a small amount (60 mL) of orange juice or tomato juice, and administer immediately. Rinse the glass with 2 times or more juice to ensure the entire dose is taken, and drink immediately. After opening the capsule, do not chew or crush the contents before taking them. Short-term treatment of active duodenal ulcer: Administer lansoprazole 15 mg orally once daily for 4 weeks. Short-term treatment of active benign gastric ulcer: Administer lansoprazole 30 mg orally once daily for 8 weeks. Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence: Administer lansoprazole 30 mg with clarithromycin 250 ∼ 500 mg and amoxicillin 1,000 mg twice daily (every 12 hours) for 7 days. Treatment may be continued for up to 14 days if necessary. Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence: Administer lansoprazole 30 mg in combination with amoxicillin 1,000 mg three times daily (every 8 hours) for 14 days. Maintenance treatment after treatment of duodenal ulcer: Administer lansoprazole 15 mg orally once daily. The comparative clinical trial period did not exceed 12 months. Treatment of nonsteroidal anti-inflammatory drug-induced gastric ulcer: Administer lansoprazole 30 mg orally once daily for 8 weeks. The comparative clinical trial period did not exceed 8 weeks. Reduction of the risk of nonsteroidal anti-inflammatory drug-induced gastric ulcer: Administer lansoprazole 15 mg orally once daily for 12 weeks. The comparative clinical trial period did not exceed 12 weeks. Short-term treatment of symptoms associated with gastroesophageal reflux disease: Administer lansoprazole 15 mg orally once daily for 8 weeks. Short-term treatment of erosive reflux esophagitis: Administer lansoprazole 30 mg orally once daily for 8 weeks. Maintenance treatment after treatment of erosive reflux esophagitis: Administer lansoprazole 15 mg orally once daily. Pathological hypersecretory conditions, including Zollinger-Ellison syndrome: The lansoprazole dose for pathological hypersecretory conditions varies by patient. Treatment in adults is usually initiated at 60 mg once daily. The dose should be adjusted according to the patient's needs and may be continued for as long as it is clinically effective. Doses of 90 mg twice daily have been administered. If the daily dose exceeds 120 mg, it should be divided. Since clearance of this medicine is reduced in elderly patients, dose adjustment is necessary. Do not exceed a daily dose of 30 mg. Since metabolism and excretion of this medicine may be delayed in patients with hepatic impairment, administer with caution, including dose adjustment as appropriate.

Child dose

Pediatric patients and adolescents aged 12 ∼ 17 years — Short-term treatment of symptoms associated with nonerosive gastroesophageal reflux disease: 15 mg once daily for 8 weeks Pediatric patients and adolescents aged 12 ∼ 17 years — Short-term treatment of erosive reflux esophagitis: 30 mg once daily for 8 weeks Pediatric patients aged 1 ∼ 11 years, weighing 30 kg or less — Short-term treatment of symptoms associated with gastroesophageal reflux disease and erosive reflux esophagitis: 15 mg once daily for 12 weeks Pediatric patients aged 1 ∼ 11 years, weighing more than 30 kg — Short-term treatment of symptoms associated with gastroesophageal reflux disease and erosive reflux esophagitis: 30 mg once daily for 12 weeks

Precautions

This medication should not be administered to those with a history of allergy or hypersensitivity to specific components or benzimidazole derivatives. Additionally, those with allergies to penicillin or macrolide antibiotics, as well as those currently taking specific heart-related medications, should avoid use. It should not be used in patients who are pregnant or have genetic problems such as lactose intolerance. Caution should be exercised in patients with a history of drug hypersensitivity, those with impaired liver function, elderly patients, nursing women, and children. Serious side effects such as allergic reactions, blood abnormalities, liver dysfunction, or severe skin reactions may occur during treatment, so immediate consultation with a physician is required if any abnormal symptoms arise. Long-term use may lead to nutrient deficiencies such as vitamin B12 deficiency or hypomagnesemia, necessitating regular examinations. This medication inhibits gastric acid secretion and may interfere with the absorption of some drugs or affect their blood concentration, so caution should be taken when used in combination with other medications. Especially when taken with HIV treatments, some antibiotics, anticoagulants, etc., consultation with a physician is advised. Use should be avoided during pregnancy due to potential effects on the fetus, and nursing should be discontinued or avoided if medication is required. Safety and efficacy have not been fully established in children, so caution is necessary. In elderly patients, it is advisable to start at a lower dose due to decreased body function. In cases of overdose, gastric emptying or symptomatic treatment may be required, and it is not removed by dialysis. This medication should be kept out of reach of children and should not be transferred to another container. Dizziness or drowsiness may occur during use, so caution is needed when driving or operating machinery.

Side effects

Anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute interstitial nephritis, urticaria, generalized rash, facial edema, dyspnea, shock, pancytopenia, agranulocytosis, hemolytic anemia, granulocytopenia, thrombocytopenia, anemia, jaundice, AST elevation, ALT elevation, toxic liver dysfunction, toxic epidermal necrolysis, Stevens-Johnson syndrome, DRESS syndrome, eosinophilic pneumonia, fever, cough, abnormal lung sounds, interstitial nephritis, acute renal failure, membranous colitis, hematochezia, abdominal pain, frequent diarrhea, headache, diarrhea, abdominal distension, allergic reaction, back pain, weakness, candidiasis, cancer, chills, chest pain, edema, fever, flu-like symptoms, halitosis, infection, malaise, nuchal rigidity, pelvic pain, angina pectoris, arrhythmia, bradycardia, tachycardia, cerebrovascular accident, cerebral infarction, hypertension, hypotension, migraine, myocardial infarction, palpitations, vasodilation, syncope, asthma, bronchitis, increased cough, epistaxis, hemoptysis, hiccups, pneumonia, upper respiratory tract infection, laryngeal tumor, pulmonary fibrosis, pharyngitis, pleural disorder, respiratory disorder, rhinitis, sinusitis, wheezing, abnormal stool, enteritis, gastritis, gastrointestinal abnormalities, gastrointestinal diseases, gastrointestinal bleeding, loss of appetite, bezoar, pyloric spasm, cholelithiasis, constipation, dry mouth, thirst, dyspepsia, dysphagia, belching, esophageal stricture, esophageal ulcer, esophagitis, stool discoloration, distension, gastric nodule, gastric fundus polyp, gastroenteritis, gastrointestinal hemorrhage, hematemesis, increased appetite, increased salivation, anal bleeding, stomatitis, tongue disease, glossitis, gingival bleeding, late-onset lean body mass condition, colitis, vomiting, nausea, gastrointestinal candidiasis, rectal diseases, rectal hemorrhage, diabetes mellitus, goiter, hypothyroidism, anemia, bleeding, lymphadenopathy, vitamin deficiency, gout, hyperglycemia, hypoglycemia, dehydration, weight gain, weight loss, peripheral edema, bone diseases, joint diseases, leg cramps, arthritis, arthralgia, musculoskeletal pain, myalgia, myasthenia gravis, ptosis, synovitis, anxiety, amnesia, anxiety, apathy, delirium, depression, dizziness, syncope, hallucinations, hemiparesis, exacerbation of hostility, decreased libido, increased libido, neurosis, sensory disturbance, abnormal thoughts, seizures, dementia, depersonalization, diplopia, hyperkinesis, hypertonia, sensory impairment, insomnia, sleep disorders, drowsiness, tremors, acne, hair loss, pruritus, rash, urticaria, contact dermatitis, dry skin, nail disease, skin cancer, skin diseases, sweating, abnormal vision, amblyopia, blepharitis, cataracts, conjunctivitis, dry eyes, ear disease, eye disease, glaucoma, altered smell, photophobia, retinal degeneration, loss of taste, blurred vision, deafness, eye pain, otitis media, altered taste, tinnitus, visual field constriction, urinary disturbance, nephralgia, penile diseases, testicular diseases, urethral pain, polyuria, urinary frequency, urinary retention, menstrual irregularities, chest tenderness, chest expansion, gynecomastia, diabetes, hematuria, erectile dysfunction, renal stones, hepatotoxicity, vomiting, pancreatitis, taste disturbance, aplastic anemia, thrombocytopenia, thrombotic thrombocytopenic purpura, eosinophilia, hypomagnesemia, Clostridium difficile-associated diarrhea, fracture, myositis, erythema multiforme, speech disorder, urinary retention, ALP elevation, LDH elevation, γ-GTP elevation, weakness, hyponatremia, total cholesterol elevation, total cholesterol reduction, tongue paralysis, lip paralysis, limb paralysis, abdominal pain, constipation, abdominal fullness, heartburn, gastroesophageal reflux, dyspnea, vomiting symptoms, dizziness, drowsiness, paralysis, depressive state

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air and moisture, at room temperature between 1 and 30 degrees Celsius. Proper storage helps maintain the medication's effectiveness and prevents degradation.

Appearance and packaging

Appearance

White to light brown granules contained in a white hard capsule for the upper and lower parts.

Package unit

28 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.